Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYang XieNanchang UniversityQCQingqing CaiNext Generation Technology (United States)HLHaisheng LiuHebei Medical University

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates manageable safety and high response rates for CN201 in relapsed refractory B-cell lymphoma, suggesting potent antitumor activity.

Key Points

  • The bispecific antibody CN201 showed high antitumor activity and low cytokine release syndrome incidence in relapsed refractory B-cell non-Hodgkin lymphoma.
  • An objective response rate of 77% and complete remission rate of 22% were achieved in 22 evaluable patients receiving target doses of 5 mg or higher.
  • Phase I dose-escalation evaluation in 58 adult patients indicated manageable toxicity with no grade 3 or higher cytokine release syndrome reported.

Cite This Study

Xie et al. (2024) studied this question.

synapsesocial.com/papers/68e6706cb6db6435875fb2echttps://doi.org/10.1200/jco.2024.42.16_suppl.7040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.2024 · 2 citations
  2. 2Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma2025
  3. 3Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025 · 1 citations
  4. 4Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma2026 · 1 citations
  5. 5Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.2024 · 3 citations